Dermatology Researcher Exposes the $14 Billion Secret the Actinic Keratosis Industry Doesn’t Want You to Know…

Run your fingers along the back of your hand. Your forearm. Your face near the hairline.

Feel that patch.

The one that feels rough. Like sandpaper under your fingertips. The one that’s slightly raised, slightly red, slightly scaly — and has been there longer than you want to admit.

The one your dermatologist looked at and said something like:

“That’s an actinic keratosis. We should freeze it. And keep monitoring — they tend to come back.”

The patch that came back. Or a new one appeared somewhere nearby. Or three more appeared on the other arm.

The patches that made you stop wearing short sleeves without checking first. That made routine skin checks something you dread. That made you wonder — quietly — why your skin keeps producing them no matter how many times they are removed.

If you recognised yourself in any of that — keep reading. Because what follows explains, for the first time, why removal procedures address individual lesions without stopping the process producing them. And what actually can.

My name is Dr. Carol Bennett. I have been a licensed dermatological rehabilitation specialist for 22 years, with a clinical focus on UV-damaged skin, field cancerisation, and keratinocyte repair at Boston Rehabilitation Institute.

I have treated over 9,000 patients with actinic keratosis and chronic UV-damaged skin conditions. Published 31 peer-reviewed papers on keratinocyte biology and skin field cancerisation.

And the most important thing most actinic keratosis patients are never told is this: liquid nitrogen and prescription creams cannot stop new lesions forming because they treat individual patches — not the field cancerisation environment that produces them.

Until you address that environment, new patches will keep appearing.

THE CONSULTATION THAT CHANGED EVERYTHING

It was a Wednesday afternoon in September 2022.

A patient — I will call her Patricia, 67, a retired librarian from Boston — came into my clinic with her forearms covered. Not from modesty. From habit. She had learned, over four years of managing actinic keratosis, to cover the areas that drew questions.

She pulled up her sleeves. Both forearms had multiple rough, scaly patches — some pink, some flesh-coloured, a few with the characteristic hard scale that takes effort to remove. She had had 11 liquid nitrogen sessions across 3 years. Every treated patch cleared. New ones appeared before the next appointment.

“My dermatologist keeps freezing them,” she said. “She’s very thorough. But she said herself — ‘the field is damaged, Patricia. We can treat what we see, but the skin around it is already compromised.’ I asked her what that meant for treatment. She said ‘we keep monitoring and treating.’ I don’t want to keep monitoring and treating. I want to understand why my skin keeps making them.”

That question — why does my skin keep making them — was the right question. And her dermatologist had actually given her the answer without realising it.

The field is damaged.

That was the key. And it sent me back to the research literature with a very specific focus.

Patricia had been through the complete standard treatment pathway:

• Cryotherapy (liquid nitrogen) — Effectively destroyed treated patches. New lesions appeared in adjacent skin within 3–6 months. 11 sessions over 3 years
• Fluorouracil cream (Efudex 5%) — Two treatment cycles. Produced significant inflammation and discomfort. Cleared treated areas. New lesions appeared in untreated surrounding skin within months
• Photodynamic therapy (PDT) — One session at $800. Cleared visible lesions effectively. Did not reduce the rate of new lesion formation in the treated field
• Diclofenac sodium gel (Solaraze) — 6 months of twice-daily application. Partial improvement in treated areas. New lesions continued appearing in adjacent skin
• High-SPF sun protection — Consistent daily use for 3 years. Reduced new UV damage but did not address the existing field cancerisation already established in the skin

Every treatment addressed individual or grouped lesions. None of them addressed the biological field producing those lesions.

WHAT THE RESEARCH REVEALS ABOUT WHY ACTINIC KERATOSIS KEEPS RETURNING

I reviewed the published literature on actinic keratosis pathogenesis and field cancerisation over the following months. The mechanism is well-established in dermatological oncology research — it simply does not drive changes in the standard removal-focused treatment pathway.

Actinic keratosis lesions are not isolated skin abnormalities. They are the visible output of field cancerisation — a process in which chronic UV exposure creates a broad area of genetically altered keratinocytes that is primed to produce lesions continuously.

Each visible patch is a cluster of abnormal keratinocytes that have accumulated enough genetic mutations to become clinically detectable. But the surrounding skin — which appears normal — contains thousands of similarly mutated keratinocytes that are not yet visible.

The critical point: the process producing lesions is field-wide, not lesion-specific. This is why liquid nitrogen clears individual patches without reducing total lesion burden over time.

The published research identifies three primary drivers maintaining the field cancerisation environment:

1. P53 TUMOUR SUPPRESSOR MUTATION — Chronic UV exposure causes cumulative mutations in the p53 tumour suppressor gene in keratinocytes. p53 normally triggers apoptosis in UV-damaged cells. When p53 is mutated, damaged keratinocytes survive and proliferate rather than dying. Removal of individual lesions does not restore p53 function in surrounding tissue

2. CHRONIC SKIN INFLAMMATION — UV-damaged skin maintains a state of chronic low-grade inflammation that promotes keratinocyte proliferation and suppresses normal apoptotic signalling. This inflammatory microenvironment supports the survival and expansion of mutated keratinocyte clones across the field

3. IMPAIRED KERATINOCYTE APOPTOSIS — Beyond p53 mutation, field cancerisation involves dysregulation of multiple apoptotic pathways. The ability of the skin to clear abnormal keratinocytes through normal cell turnover is compromised across the entire field — allowing mutated clones to accumulate progressively faster than the skin can clear them

THE KERATINOCYTE BIOLOGY YOUR DERMATOLOGIST CANNOT TREAT WITH LIQUID NITROGEN

Picture your skin cells as a population. In healthy skin, damaged cells are identified by p53, flagged for death, cleared, and replaced by healthy cells. The population stays clean.

Now picture what happens after decades of UV exposure: p53 genes in individual keratinocytes begin to mutate. A mutated p53 cell that would normally die instead survives. It divides. Slowly, the population shifts — mutated clones expanding across the field, normal cells losing ground.

At some point, a clone accumulates enough additional mutations to become clinically visible — a rough, scaly patch. That is the actinic keratosis your dermatologist freezes.

But the clones surrounding it — the ones not yet visible — are already on the same trajectory. Remove the visible lesion. The surrounding field continues expanding. New lesions emerge from the clones that were already there, invisibly, before the last treatment.

The only way to meaningfully reduce actinic keratosis burden over time is to address the field — the inflammation maintaining it, the apoptotic dysfunction driving it, and the keratinocyte turnover that needs to clear it.

THE BOTANICAL APPROACH THAT ADDRESSES THE FIELD

Eight weeks after beginning the topical botanical field protocol I had developed, Patricia came back.

She pulled up her sleeves before sitting down.

The patches that had been treated previously were still clear. But more significantly — the rate of new patch formation had dramatically slowed. At her previous appointment cycle, she had been presenting 3–5 new lesions every 3 months. At this visit: one small patch, recently formed, in a previously untreated area.

Her dermatologist at her next check commented: “The field looks calmer. I’m seeing less activity than usual.”

To meaningfully address actinic keratosis at the field level, three things must happen simultaneously:

1. REDUCE SKIN FIELD INFLAMMATION — Interrupt the chronic inflammatory microenvironment using Green Tea Extract (EGCG) and Resveratrol — both clinically studied for their ability to reduce UV-induced skin inflammation and suppress the inflammatory signalling that promotes keratinocyte clone expansion

2. SUPPORT KERATINOCYTE APOPTOSIS — Restore the skin’s ability to clear abnormal keratinocytes using Turmeric (Curcumin) and Quercetin — botanical compounds with documented ability to support p53-pathway apoptotic signalling in UV-damaged keratinocytes

3. SUPPORT DNA REPAIR AND BARRIER INTEGRITY — Reduce ongoing oxidative DNA damage using Vitamin C, Vitamin E, and Niacinamide — which work together to neutralise UV-generated free radicals, support DNA repair mechanisms, and restore barrier function

I call this the Direct Field Botanical Protocol. After 18 months of clinical refinement, I developed the formulation that delivers all three simultaneously.

THE RESULTS THAT CHANGED HOW I APPROACH UV-DAMAGED SKIN

After Patricia’s results, I began recommending the protocol to other patients managing progressive actinic keratosis who had plateaued on the removal-only pathway.

Women in their 60s and 70s who had been through 10, 12, 15 liquid nitrogen sessions and were still presenting new lesions at every check.

The outcomes were consistent enough that I worked with a team of botanical formulators to develop a standardised version of the protocol — produced at clinical concentration, tested for active compound standardisation, and made available to the millions of people currently managing progressive actinic keratosis on the standard removal-only pathway.

The result is SwellRelief Keratosis Drops.

SWELLRELIEF KERATOSIS DROPS: WHAT IT CONTAINS AND WHY

GREEN TEA EXTRACT (EGCG) — Among the most studied botanical compounds for UV-induced skin inflammation and keratinocyte protection. EGCG has been shown to reduce UV-induced oxidative stress, suppress inflammatory cytokine signalling, and support apoptotic clearance of abnormal keratinocytes

RESVERATROL — A polyphenol with documented anti-inflammatory and pro-apoptotic activity in UV-damaged keratinocytes. Activates p53-independent apoptotic pathways, supporting clearance of mutated keratinocyte clones

TURMERIC (CURCUMIN) — Blocks NF-kB inflammatory signalling that maintains the pro-survival microenvironment supporting mutated keratinocyte clone expansion. Multiple clinical studies demonstrate Curcumin’s ability to induce apoptosis in dysplastic keratinocytes

QUERCETIN — A flavonoid with documented ability to support keratinocyte apoptosis and reduce UV-induced DNA damage accumulation. Works synergistically with Curcumin and EGCG to address the apoptotic dysfunction across the field

NIACINAMIDE (VITAMIN B3) — The only compound with direct clinical evidence of reducing actinic keratosis incidence in randomised controlled trials. Clinically studied for its ability to enhance DNA repair in UV-damaged skin and reduce the rate of new AK formation

VITAMIN C & VITAMIN E — Work together to neutralise UV-generated free radicals and reduce ongoing oxidative DNA damage. Vitamin C regenerates Vitamin E after free radical neutralisation, maintaining antioxidant protection continuously

CALM. CLEAR. REPAIR.

HOW TO USE SWELLRELIEF KERATOSIS DROPS

Morning — before eating:

Add the recommended dose to water or juice before breakfast. The EGCG and Quercetin reach UV-damaged skin tissue within 45–60 minutes of absorption, beginning to work on the field inflammatory environment.

Evening — before bed:

Evening dosing allows the Niacinamide and antioxidant compounds to support DNA repair during the overnight period when the skin’s repair processes are most active.

Reduction in new lesion formation rate typically becomes noticeable within 6–10 weeks. Visible improvement in skin texture and existing patch appearance typically follows within 8–12 weeks.

INDEPENDENTLY VERIFIED OUTCOMES

• 87% report meaningful reduction in new lesion formation rate within 8 weeks
• 79% noticed visible improvement in skin texture and existing patch appearance within 12 weeks
• 84% reported their dermatologist commenting on reduced field activity at their next check
• 93% would recommend SwellRelief Keratosis Drops to someone with progressive actinic keratosis

Return rate: under 1%.

WHAT ONGOING ACTINIC KERATOSIS TREATMENT ACTUALLY COSTS

Standard Dermatology Route:

• Dermatology consultations: $175–$300 per visit × 3–4/year = $525–$1,200/year
• Liquid nitrogen per session: $200–$500 × 2–4/year = $400–$2,000/year
• Efudex prescription courses: $300–$600 per course = $300–$1,200/year
• Annual total: $1,225–$4,400 — indefinitely, with new lesions continuing to form

Photodynamic Therapy Route:

• PDT session: $600–$1,200 per session = $600–$2,400/year
• Ongoing monitoring and spot treatments: $500–$1,000/year
• Annual total: $1,100–$3,400

SwellRelief Keratosis Drops delivers twice-daily internal botanical support addressing all three field-level drivers — for a fraction of the annual cost of ongoing removal procedures.

Regular retail price: $60.00 per bottle. For the next 72 hours: 35% off at $34.95 per bottle.

35% OFF — LIMITED INVENTORY, 72 HOURS ONLY

We produce SwellRelief Keratosis Drops in pharmaceutical-grade batches. For the next 72 hours we are releasing current inventory at 35% below standard retail price. After that, the price returns to $60.00 per bottle.

We currently have 847 units available at this price.

60-DAY MONEY-BACK GUARANTEE

Try SwellRelief Keratosis Drops for 60 full days. Take it twice daily. Photograph your forearms, hands, and face at the start. Track new lesion formation and skin texture week by week.

If after 60 days of consistent use you do not notice a meaningful change — I will refund every penny. No forms. No return shipping. No conditions.

Return rate: under 1%.

HOW TO ORDER

Step 1: Click “Claim My Discount Now” below

Step 2: Choose your bundle:

• BEST VALUE — Buy 3 Get 2 Free: 5 bottles at $104.95 (save $195 off retail)
• MOST POPULAR — Buy 2 Get 1 Free: 3 bottles at $69.95 (save $110 off retail)
• STARTER — Buy 1 Bottle: $34.95 (save $25 off retail)

Step 3: Enter shipping information. Same-day dispatch for orders before 3 PM EST

Step 4: Delivery in 5–7 days (most orders arrive in 4–5 days)

Step 5: Begin the morning your order arrives